Allogene Therapeutics, Inc. (ALLO) short interest & options flow
NASDAQAllogene Therapeutics enters September with an unusual structural tension: Pfizer holds a 13D activist stake in the company while short sellers remain deeply dug in at more than a quarter of the free float. The short side of the ledger is hard to ignore. Short interest is running at 26.3% of the free float — one of the highest readings in the clinical-stage cell therapy space — and…
ALLO short interest surges 26% in one week to 28.2% of float, highest level in months amid biotech selloff.
- Market cap
- $367M
- Next earnings
- 12 Mar 2027
Key data as of 10 Nov 2026
Latest signals on ALLO
- Short Interest
ALLO short interest surges 26% in one week to 28.2% of float, highest level in months amid biotech selloff.
ALLO news and analysis
RSSNo long-form analysis yet for ALLO. Pulse alerts and the live data picture are available on ORTEX.
Open ALLO on ORTEX →Want the live picture for ALLO?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALLO — free to start on ORTEX.
Sign up for free →Open ALLO on ORTEX